Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins

Executive Summary

Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.


Related Content

Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Perrigo's Return To OTC Roots Restoring Investor Confidence
GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition
Perrigo Starts Branded Consumer Product Rescue Mission In Belgium
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
OTC Nexium 24HR Rides Blockbuster History Into Full Field Of Competitors
FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts